Latest Alpha-synuclein Stories
Researchers at the Keck School of Medicine of the University of Southern California (USC) have uncovered structural clues about the protein linked to Parkinson's disease (PD), which ultimately could lead to finding a cure for the degenerative neurological disorder.
Researchers at North Carolina State University have figured out how copper induces misfolding in the protein associated with Parkinson's disease, leading to creation of the fibrillar plaques which characterize the disease.
As Parkinson's Awareness Month gets underway, a Canadian-led international study is providing important new insight into Parkinson's disease and paving the way for new avenues for clinical trials.
A protein pathway that may hold the secret to understanding Parkinson's disease has been discovered and explained by Iowa State University researchers.
In new research from Saint Louis University, investigators have found evidence that a toxin produced by the brain is responsible for the series of cellular events that lead to Parkinson's disease.
A team of scientists from The Scripps Research Institute and the University of California, San Diego (UCSD) have developed a novel technique to observe previously unknown details of how folded structures are formed from an intrinsically disordered protein.
The study, published in the Journal of Clinical Investigation, reveals that damaged alpha-synuclein proteins (which are implicated in Parkinson's disease) can spread in a 'prion-like' manner, an infection model previously described for diseases such as BSE (mad cow disease).
In a study published today in the Proceedings of the National Academy of Sciences (Early Edition ahead of print), a team of researchers from the Kennedy Krieger Institute and four collaborating institutions, identified a new and unexpected biological pathway that appears to contribute to the development of glaucoma and its resulting vision loss.
VIENNA, December 16, 2010 /PRNewswire/ -- With a grant of USD 475,000, the Michael J. Fox Foundation is funding preclinical development of a vaccine against Parkinson's disease by AFFiRiS AG.
CRANBURY, N.J., Dec. 8, 2010 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company focused on developing treatments for rare diseases, today announced that it has been awarded a second grant from The Michael J.
- Large; stout; burly.